Clinical trial
Open access
Oct 2026
Phase 3 randomized trial of latozinemab in frontotemporal dementia due to GRN mutations
Abstract INTRODUCTION Heterozygous progranulin gene mutations causing frontotemporal dementia (FTD‐GRN) are associated with deficiency in progranulin (PGRN). Latozinemab is a human monoclonal immunoglobulin G1 (IgG1) antibody designed to elevate PGRN levels in people with heterozygous loss‐of‐function (LOF) GRN mutatio...
Adam Simmons, B. Boeve, I. Le Ber et al.
· Alzheimer's & Dementia · 0 citations